20 completed. 20 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 20 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma anlotinib hydrochloride - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Peking Union Medical College Hospital | 27 | 2021-04-30 | 2024-06-12 |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Cabozantinib 40 mg - Neuroendocrine Tumor, Anaplastic Thyroid Cancer | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 93 | 2020-10-07 | 2025-06-19 |
| The Efficacy and Safety of Temozolomide in Patients With MPPGL Temozolomide capsule - Pheochromocytoma, Metastatic, Paraganglioma, Malignant | Phase 2 | Completed | Peking Union Medical College Hospital | 62 | 2019-10-01 | 2023-05-15 |
| the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma Dexmedetomidine, General anesthetic - Pheochromocytoma | Phase 2 | Completed | National Cancer Institute, Egypt | 30 | 2019-06-30 | 2021-09-01 |
| Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-31 | 2024-02-20 |
| Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration - Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2015-02-17 | 2025-07-31 |
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Axitinib (AG-013736) - Pheochromocytoma, Paraganglioma | Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2013-10-19 | 2021-01-06 |
| Dovitinib in Neuroendocrine Tumors Dovitinib - Advanced Metastatic Paraganglioma, Advanced Metastatic Pheochromocytoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 8 | 2012-06-01 | 2020-04-14 |
| Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study - Carney Complex, Chondrosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2012-03-01 | 2018-09-21 |
| First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Sunitinib, Placebo - Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 78 | 2011-12-22 | 2022-08-04 |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Fostamatinib disodium - Head and Neck Neoplasms, Pheochromocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2009-04-01 | 2015-09-30 |
| Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Sunitinib - Paraganglioma, Pheochromocytoma | Phase 2 | Completed | University Health Network, Toronto | 25 | 2009-02-01 | 2024-10-17 |
| RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid RAD001 - Pheochromocytoma, Extra-adrenal Paraganglioma | Phase 2 | Completed | Seoul National University Hospital | 33 | 2008-07-01 | 2015-05-20 |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Ultratrace Iobenguane (MIBG) I 131 - Pheochromocytoma, Paraganglioma | Phase 1 / Phase 2 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2007-04-01 | 2016-07-13 |
| Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Indium-111 pentetreotide - Neuroendocrine Tumors | Phase 2 / Phase 3 | Completed | Radio Isotope Therapy of America | 200 | 2005-08-01 | 2023-04-03 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer isolated perfusion, melphalan - Cancer | Phase 2 | Completed | Delcath Systems Inc. | 56 | 2004-09-01 | 2013-10-23 |
| 131MIBG to Treat Malignant Pheochromocytoma [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG - Pheochromocytoma | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 32 | 2001-12-05 | 2017-07-02 |
| Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors cisplatin, doxorubicin hydrochloride, tamoxifen citrate - Adrenocortical Carcinoma, Brain and Central Nervous System Tumors | Phase 2 | Completed | Ottawa Regional Cancer Centre | 30 | 1994-05-01 | 2013-07-10 |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors 131I-MIBG - Pheochromocytoma, Paraganglioma | Phase 2 | Completed | University of California, San Francisco | 50 | 1991-05-01 | 2018-09-18 |
Pheochromocytoma (18) · Neoplasm Metastasis (4) · Neoplasms (4) · Neuroendocrine Tumors (4) · Paraganglioma, Extra-Adrenal (4) · Carcinoma, Medullary (3) · Somatostatinoma (3) · Carcinoid Tumor (2) · Carcinoma, Hepatocellular (2) · Head and Neck Neoplasms (2) · Liver Neoplasms (2) · Pancreatic Neoplasms (2) · Thyroid Carcinoma, Anaplastic (2) · Vipoma (2)
Neoplasms by Histologic Type (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neoplasms (16) · Neuroendocrine Tumors (16) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Adenocarcinoma (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
3-Iodobenzylguanidine (3) · Sunitinib (2) · Temozolomide (2) · cabozantinib (2) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · 6-fluorodopamine (1) · Anesthetics, General (1) · Axitinib (1) · Capecitabine (1) · Cisplatin (1) · Control Groups (1) · Dexmedetomidine (1) · Doxorubicin (1) · Everolimus (1)
National Cancer Institute (NCI) (3) · Peking Union Medical College Hospital (2) · Abramson Cancer Center at Penn Medicine (1) · Columbia University (1) · Delcath Systems Inc. (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Molecular Insight Pharmaceuticals, Inc. (1) · National Cancer Institute, Egypt (1) · Ottawa Regional Cancer Centre (1) · Radio Isotope Therapy of America (1) · Seoul National University Hospital (1)
United States (12) · Canada (2) · China (2) · Netherlands (2) · Egypt (1) · France (1) · Germany (1) · Italy (1) · South Korea (1) · Spain (1)
Anli Tong (2) · Andrea B Apolo, M.D. (1) · Ashish Chintakuntlawar (1) · Camilo Jimenez (1) · Do-Youn Oh, MD, PhD (1) · Ebrahim Delpassand, M.D. (1) · Ehab H Shaker, MD (1) · Eric Baudin, MD (1) · Jaume Capdevila, M.D, Ph.D (1) · Jennifer Knox, MD, FRCPC (1) · Margaret von Mehren (1) · Marybeth Hughes, MD (1) · Paul E Oberstein, MD (1) · Paul Fitzgerald (1)
PMID 19636009, PMID 24952730, PMID 26040622, PMID 29099942, PMID 31322702, PMID 38402886, PMID 38608693
2019 (1), P30CA015083 (1)